[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Brest\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":581},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,119,0,25,[9,43,70,91,113,138,165,184,203,223,243,267,286,311,331,350,379,401,428,450,474,501,520,540,558],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054288",false,"NCT07417605","Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy.","POLARIS","Inclusion Criteria:\n\n* Adult patient ≥ 18 years of age\n* Presenting with head and neck squamous cell carcinoma\n* Completed curative treatment with external radiation therapy\n* Eligible for dynamic LAFOV FDG-PET scan for therapeutic evaluation at 3 months\n* Having given consent for the end-of-treatment consultation\n\nExclusion Criteria:\n\n* Hypersensitivity to 18F-FDG or other excipients contained in the contrast agent\n* Pregnancy or breastfeeding\n* History of treated upper gastrointestinal tract cancer\n* Other histology\n* Incomplete RTE treatment regimen\n* Refusal to participate","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","OBSERVATIONAL","This multicenter prospective observational study will evaluate the value of dynamic FDG-PET LAFOV imaging during the initial therapeutic assessment of a head and neck cancer 3 months after completion of curative radiotherapy.",[24],"Head & Neck Squamous Cell Carcinoma",[26,27,28,29],"4D dynamic analysis","post-radical inflammation","squamous cell carcinomas","FDG-PET LAFOV","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2026-04-13",{"date":38,"type":20},"2029-06-13",{"name":40,"class":41},"University Hospital, Brest","OTHER",3,{"id":44,"slug":4,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100579080","NCT06819644","Optimisation of High Flow Oxygen Therapy Settings During Hypoxaemic Respiratory Distress Based on Non-contact Measurement of Lung Volumes by Depth Camera","DiStok","Inclusion Criteria:\n\n* Patients with hypoxemic respiratory distress define by the following 4 criteria:\n* Respiratory rate ≥ 25 breaths per minutes\n* A ratio of the partial pressure of arterial oxygen (PaO2) to the FiO2 ≤ 300 mmHg while the patient is breathing oxygen at a flow rate of 10 liters per minutes or more\n* A partial pressure of arterial carbon dioxide (PaCO2) not higher than 45 mmHg\n* An absence of clinical history of underlying chronic respiratory failure\n\nExclusion Criteria:\n\n* A do-not-intubate order\n* Pregnant or lactating woman\n* Cardiogenic pulmonary edema\n* Exacerbation of asthma\n* Hemodynamic instability with use of vasopressor at significant dose (norepinephrine \\> 0.5 mg\u002Fh)\n* A Glasgow Coma Scale of 12 points of less\n* Contraindications to non-invasive ventilation\n* Urgent need for endotracheal intubation\n* High flow oxygen therapy started within 48 hours before inclusion\n* Patient under legal protection or deprived of liberty",{"count":50,"type":20},406,"INTERVENTIONAL",[53],"PHASE3","The goal of this clinical trial is to validate the interest of a strategy adjusting the flow rate delivered under high-flow oxygen (HFO) therapy according to the lung volumes measured by a new technique, in intensive care patients with hypoxemic respiratory distress (HRD).\n\nThe main question it aims to answer is:\n\n\"The use of a technique of measurement of lung pulmonary with adjustement to the flow rate can make it possible to limite intubation in patients with HRD in intensive care?\" The participants will be the patients admitted in intensive care for HRD with the need for treatment with HFO.\n\nThis participants will be randomized in :\n\n* the arm control: treated by high flow oxygen therapy according to standard procedures.\n* or in the experimental arm : treated by high flow oxygen therapy with adjustement of ventilatory parametres based on lung volume measurements, obtained by the depth camera.",[56],"Hypoxemic Respiratory Failure",[58,59,60],"flow oxygen","lung volume","depth camera","2026-06-25",{"date":63,"type":34},"2026-06-29",{"date":65,"type":34},"2026-04-08",{"date":67,"type":20},"2030-10",{"name":40,"class":41},8,{"id":71,"slug":4,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":51,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100433979","NCT04931160","B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome","BRAISES-DiaPSS","Inclusion Criteria:\n\n* Major patient\n* Suspicion of SSp (clinical or biological criteria, i.e. dry eye or oral syndrome, arthritis, parotidomegaly, neuropathy, kidney or lung disease...)\n* Patient affiliated with Social Security\n* Patient who has signed written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate\n* Pregnant and lactating woman",{"count":77,"type":20},1000,[79],"NA","The objectif is to study the diagnosis performance of the different classification criteria in reference to the gold standard consisting of the diagnosis made by expert doctors after standardized assessment, of pSS (primary Sjogren syndrome)",[82],"Sjogren's Syndrome",{"date":84,"type":34},"2026-06-26",{"date":86,"type":34},"2020-02-10",{"date":88,"type":20},"2035-02-10",{"name":40,"class":41},1,{"id":92,"slug":4,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":51,"phases":100,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":90},"100396979","NCT04449146","Scapular Positioning in Standing Position Using Sonography","3S","Inclusion Criteria:\n\n* Major patients and agreeing to participate in the study after oral and written information.\n* Care course patients for a reverse shoulder arthroplasty on a native shoulder joint\n\nExclusion Criteria:\n\n* Patients under the age of 18\n* Patients refusing to participate in the study\n* Patients whose condition does not allow informed consent\n* Patients who are subject to legal protection (safeguarding of Justice, curatorship, guardianship), persons deprived of their liberty\n* Unaffiliated patients and non-beneficiaries of a health insurance plan","99 Years",{"count":99,"type":20},30,[79],"The objective of this study is to analyse the positioning of the scapula in standing position and compared to the supine position (CT scan) in 3 dimensions (3 rotations of the scapula) using a non-radiant, portable system, combining an ultrasound probe with marker and a camera integrated into a Tablet for the three-dimensional location of the marker (probe).",[103,104],"Shoulder Osteoarthritis","Arthropathy Shoulder",[106],"Reverse Shoulder Arthroplasty",{"date":63,"type":34},{"date":109,"type":34},"2022-08-31",{"date":111,"type":20},"2026-08-31",{"name":40,"class":41},{"id":114,"slug":4,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":51,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100560627","NCT06579612","The Benefits of Individualized Follow-up With a Sport-Health Professional in the Care of Patients With Chronic Respiratory Diseases","The Benefits of Individualized Follow-up With a Sport-Health Professional in the Care of Patients With Chronic Respiratory Diseases, to Maintain Long-term Benefits After a Respiratory Rehabilitation Program","WANTTOMOVE","Inclusion Criteria:\n\n* Diagnosis of one or more chronic respiratory diseases (asthma, chronic obstructive pulmonary disease, diffuse interstitial lung disease, bronchiectasis, obstructive sleep apnea syndrome, etc.).\n* Participation in a respiratory pulmonary program\n* Have given consent\n* Patient of legal age\n* Patient affiliated to Social Security\n\nExclusion Criteria:\n\n* Any medical contraindication to the practice of adapted physical activity in rehabilitation\n* Patients under guardianship or curatorship\n* Patients deprived of their liberty\n* Patients over 80 years of age at the time of inclusion.","80 Years",{"count":122,"type":20},352,[79],"Pulmonary rehabilitation is an integral part of care for patients with chronic respiratory diseases. It improves patients' physical capacities, quality of life and symptoms, at least in the short term.\n\nThe hypothesis that patients receiving personalized support from a professional following pulmonary rehabilitation will maintain long-term benefits.\n\nThis study concerns patients with a diagnosis of one or more chronic respiratory diseases.\n\nIt is a multicenter, blinded, randomized controlled superiority trial in 2 parallel arms:\n\n* a group comparing follow-up and personalized support after a pulmonary rehabilitation program (experimental group)\n* a control group receiving only usual care",[126],"Chronic Respiratory Disease",[128,129],"chronic respiratory disease","pulmonary rehabilitation","2026-06-24",{"date":84,"type":34},{"date":133,"type":34},"2024-11-07",{"date":135,"type":20},"2029-11-07",{"name":40,"class":41},2,{"id":139,"slug":4,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":90},"100558459","NCT06551389","Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU","COLUPUS","Inclusion Criteria:\n\n* Any patient over 18 years old of the multidisciplinary consultation\n\nExclusion Criteria:\n\n* Opposition of patient",{"count":145,"type":20},300,"Systemic lupus erythematosus is a complex systemicautoimmune disease that can affect most organs of the human body.\n\nAlthough they are many recommendations on the diagnosis and managment of SLE, diagnosis and therapeutic managment is still challenging.\n\nA pluridisciplinary consultation grouping rheumatologist, nephrologist, dermatologist, gynecologist, internist and immunologists has been set up in 2009 at the university hospital of Brest.\n\nThe investigators would like to identify in a longitudinal cohort the occurrence of the different clinico-biological and immunological patterns of systemic lupus erythematosus patients during our multidisciplinary consultation.\n\nIt is now crucial to organize a standardized data collection of these patients in order to evaluate our pratices, to be able to study the epidemiology of SLE in our city, and to promote this initiative at national and international level.",[148],"Systemic Lupus Erythematosus",[150,151,152,153,154,155,156,157,158],"autoimmune diseases","joint diseases","cutaneous systemic diseases","musculoskeletal diseases","arthritis","rheumatoid","rheumatic diseases","connectivite tissue diseases","immune system diseases",{"date":61,"type":34},{"date":161,"type":34},"2020-10-13",{"date":163,"type":20},"2035-04",{"name":40,"class":41},{"id":166,"slug":4,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":172,"targetDuration":4,"studyType":51,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":137},"100533203","NCT06222762","Effect of Personalized Follow-up in Adapted Physical Activities in Subjects With Chronic Heart Failure.","Effect of a Personalized Follow-up in Adapted Physical Activities on the Long-term Benefits of Rehabilitation in Subjects With Chronic Heart Failure.","BougeTonCoeur","Inclusion Criteria:\n\n* Diagnosis of stable heart failure with NYHA stage I, II or III\n* Participation in a cardiac rehabilitation programme\n* Patient agreement\n* Patient of legal age\n* Patient affiliated to the Social Security\n\nExclusion Criteria:\n\n* Patient refusal\n* Minor patients\n* Subjects under guardianship or curatorship\n* Subjects over 80 years of age at the time of inclusion",{"count":173,"type":20},90,[79],"France has one million people with heart failure (HF). Exercise intolerance, characterised by dyspnoea, is the main clinical symptom in HF patients and a key determinant of reduced quality of life. In addition to drug and surgical treatments, cardiac rehabilitation programmes have shown benefits in heart failure patients. Lasting at least 3 weeks, these programmes improve physical abilities, quality of life and reduce the risk of hospitalisation for heart failure patients.\n\nTo date, the real challenge is no longer to prove the benefits of cardiac rehabilitation, but to find solutions to maintain its long-term effects. The transition between the end of the supervised programmes in the centre and the return home is a difficult phase for the majority of patients who do not continue regular physical activity and thus quickly lose the benefits of the programme.\n\nTo help maintain the benefits of cardiac rehabilitation, some centres offer patients programmes to continue physical activity during phase III. Although these options are often beneficial in the first few months after the end of rehabilitation compared to control groups, the long-term results are mixed. These results imply that one of these maintenance options may not be suitable for all patients. It is therefore important to propose a personalised post-rehabilitation follow-up involving the patient in the choice of physical activities to optimise the maintenance of long-term benefits.\n\nWe hypothesise that patients who receive personalised support from a sport and health professional following rehabilitation maintain long-term benefits compared to a control group who do not receive this support.",[177],"Heart Failure",{"date":84,"type":34},{"date":180,"type":34},"2024-02-13",{"date":182,"type":20},"2027-09-13",{"name":40,"class":41},{"id":185,"slug":4,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":90},"100514043","NCT05973344","Understanding and Anticipating Therapeutic and ADverse Responses in Anti-cancer Immune Checkpoint Inhibition Towards a Better Therapeutic Management of Patients","TADIG-P","* Age ≥ 18 years old\n* ECOG performance status ≤ 1\n* Must have histologically or cytologically confirmed tumour, eligible for treatment with ICI as standard-of-care alone or in combination with another ICI, ICI with chemotherapy, ICI with radiotherapy, or ICI with targeted therapy with no restrictions on number of prior systemic therapies\n* Adequate bone marrow function as defined below\n\n  * Absolute neutrophil count ≥ 1500\u002FµL or 1.5x109\u002FL\n  * Hemoglobin ≥ 9 g\u002FdL\n  * Platelets ≥ 100000\u002FµL or 100x109\u002FL\n* Adequate liver function as defined below\n\n  * Serum total bilirubin ≤ 1.5 x ULN. In case of known Gilbert's syndrome \\\u003C 3xUNL is allowed\n  * AST (SGOT)\u002FALT (SGPT) ≤ 3.0 x ULN\n  * Alkaline phosphatase ≤ 3.3 x ULN\n* Adequate renal function as defined below\n\n  \\_- Creatinine ≤ 1.5 x UNL or creatinine clearance \\> 60 mL\u002Fmin\n* Patient monitored for their cancer at CHU of Brest\n* Did not oppose for their samples and clinical data to be used for translational research\n* Non-opposition form obtained prior to any study related procedure\n\nExclusion Criteria:\n\n* Patient with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study\n* Patient already receiving ICI\n* Primary immunodeficiency and\u002For history of allogenic transplantation\n* Current active infection\n* Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection)\n* Subject of guardianship (tutorship, curatorship)\n* Active pregnancy",{"count":191,"type":20},200,"The goal of this observational study is to explore the value of blood biomarkers for the purpose of predicting irAE development in cancer patients treated with immune checkpoint inihibitors (ICI) alone or in combination with other treatments (chemotherapy, radiotherapy and targeted therapy).\n\nData and blood samples will be collected from participants at different time points as part of routine follow-up visits. Data and blood samples will be analysed. Analysis will include the characterization of immune cells by mass and flow cytometry.",[194],"Cancer",[196],"immunotherapy",{"date":84,"type":34},{"date":199,"type":34},"2024-02-09",{"date":201,"type":20},"2030-02-09",{"name":40,"class":41},{"id":204,"slug":4,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":209,"targetDuration":211,"studyType":21,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":90},"100491375","NCT05678309","Establishment of a Patient Library in Patients With Pruritus Sine Materia","PRURITHEQUE","Inclusion Criteria:\n\n* Diagnosis of pruritus sine materia\n* Collection of consent\n* Adult\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study",{"count":210,"type":20},175,"5 Years","Very little is currently known about the pathophysiology of pruritus sine materia according to the etiology. The creation of this cohort should make it possible to improve our clinical and biological knowledge according to the etiology, by collecting blood, skin, feces, and clinical data.",[214,215,216],"Pruritus","Chronic Pruritus","Itch",{"date":61,"type":34},{"date":219,"type":34},"2023-06-16",{"date":221,"type":20},"2033-06",{"name":40,"class":41},{"id":224,"slug":4,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":211,"studyType":21,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":90},"100480198","NCT05532865","Prospective Cohort of Patients With Systemic Sclerosis at Brest University Hospital With Biobanking","Prospective Cohort of Patients With Systemic Sclerosis at Brest University Hospital and Constitution of a Biobank","SCLEROBREST","Inclusion Criteria:\n\n* Major patient with systemic sclerosis defined according to the EULAR 2013 criteria (see Appendix 1)\n* Patient evaluated within the framework of the reference center for rare autoimmune diseases of the CHU of Brest.\n* Patient affiliated to the social security system\n* Patient having signed a written informed consent.\n\nExclusion Criteria:\n\n* Minor\n* Patient under legal protection (guardianship, curatorship)\n* Refusal to participate\n* Patient unable to consent\n* Pregnant or breastfeeding woman\n* Hemoglobin (Hb) level \\\u003C 7g\u002Fdl",{"count":231,"type":20},100,"This study corresponds to a monocentric prospective cohort of adult patients with systemic sclerosis.\n\nIt will allow the constitution of an organized collection of longitudinal clinical data as well as collection of biological samples, including blood samples, as well as stool sample and skin swab for microbiota analysis.",[234],"Systemic Sclerosis",[234,236],"Patient library",{"date":84,"type":34},{"date":239,"type":34},"2022-10-13",{"date":241,"type":20},"2032-10-13",{"name":40,"class":41},{"id":244,"slug":4,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":250,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":51,"phases":254,"briefSummary":255,"conditions":256,"keywords":260,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":90},"100465409","NCT05340348","Patientheque in Patients With a Psychosis","Formation of a Patientheque in Patients With a Beginner Psychosis","LONGIPEP","Inclusion Criteria:\n\n* Major and or minor aged 15 to 30 assessed within the CEVUP (Consultation for the Assessment of Psychological Vulnerability) and cared for at the psychiatry center as part of a first psychotic episode (Diagnosis CIM 10: F20 -F29 first hospitalization). These patients are referred by care and medico-social partners (general practitioners, school doctors, school nurses, educators, addictologists, psychiatrists\n* \"At risk\" status for psychotic disorder (GRD, APS, BLIPS group) or psychosis threshold during the CAARMS test (psychometric scale for the assessment of psychotic symptoms)\n* Consent of the patient or his legal guardian\n\nExclusion Criteria:\n\n* History of psychosis for more than one year\n* \"Not at risk\" status for psychotic disorder on the CAARMS (psychometric scale for the assessment of psychotic symptomatology)\n* IQ\\\u003C70 (WAIS)\n* Neurological disorder or other health problem that may explain the disorders\n* Refusal to participate - History of psychosis for more than one year","15 Years","30 Years",{"count":253,"type":20},250,[79],"Establishment of a patient library for patients who have had a first psychotic episode and who have an \"at risk\" status for psychotic disorder (GRD, APS, BLIPS group) or a psychosis threshold during CAARMS administration. Samples are taken on inclusion, at 2 years, and if relapse or significant clinical event within 5 years of inclusion, on 250 patients for 10 years.",[257,258,259],"Schizophrenia Prodromal","Schizophrenia, Childhood","Schizophrenia",[259,236],{"date":84,"type":34},{"date":263,"type":34},"2022-07-25",{"date":265,"type":20},"2032-07-25",{"name":40,"class":41},{"id":268,"slug":4,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":274,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":275,"targetDuration":4,"studyType":51,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":90},"100467294","NCT05364892","Biocollection of Patients With ANCA Associated Vasculitis","Biocollection of Patients With ANCA Associated Vasculitis Diagnosed Within the CERAINO Autoimmune Disease Reference Center, Part of the Global BRAISE Project (B-dependent Rare AutoImmune DiseaSES","ANCA","Inclusion Criteria:\n\n* Major patients with no upper age limit.\n* Patients assessed as part of the reference centre for rare autoimmune diseases at the CHRU in Brest.\n* Patients for whom a diagnosis of ANCA-associated vasculitis is made by the physician in charge of the patient, according to the definitions of the Chapel-Hill Consensus Conference.\n* Patient affiliated with Social Security\n* Patient who has signed written informed consent\n\nExclusion Criteria:\n\n* Minor\n* Patients unable to consent.\n* Patients refusing to participate in research\n* Patient under legal protection (tutelage, curatorship)\n* Pregnant or lactating women\n* Hemoglobin (Hb) \\\u003C 7g\u002FdL",true,{"count":231,"type":20},[79],"As rare disease, vasculitis affects a small number of patients, the cohorts available in the literature are few and the pathophysiological mechanisms remain to be elucidated. The collection of standardized data within a patientheque as part of a multi-year follow-up will facilitate the study of the characteristics of these diseases. This may, in particular, address the main objective of identifying predictors of relapse, as well as secondary objectives for predictive factors of mortality, infectious, cardiovascular or neoplastic complications that affect the prognosis of vasculitis in order to establish a more appropriate management of the patients concerned.",[279],"ANCA-associated Vasculitis",{"date":61,"type":34},{"date":282,"type":34},"2022-10-27",{"date":284,"type":20},"2032-10-27",{"name":40,"class":41},{"id":287,"slug":4,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":51,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":310},"100468046","NCT05374681","Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization","LEADH: Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization : Liquid Embolic Agent for the Treatment of Chronic subDural Hematoma a Randomized Control Study","LEADH","Inclusion Criteria:\n\n* Patient with a more than 10 mm CSH confirmed by NCCT\n* CSH localized to convexity\n* Patient aged 18 years or more at the time of the enrollment\n* Patient beneficiary from health insurance\n\nExclusion Criteria:\n\n* Any contraindication as required per angiogram procedure (severe renal failure ≥ 4, allergy…)\n* Pre-existing severe disability resulting in baseline mRS score \\> 3\n* Life expectancy of less than 6 months due to another cause than CSH\n* Patient under legal protection or deprived of liberty by a judicial or administrative decision\n* Pregnant or breastfeeding women\n* Vulnerable persons unable to give consent",{"count":294,"type":20},550,[79],"Chronic subdural hematomas (CSH) are collections of blood in the subdural space. CSH are becoming the most common cranial neurosurgical condition among adults, and a significant public health problem, due to an increasing use of anticoagulant and antiplatelet medication in an ageing population. Symptomatic CSH, or CSH with a significant mass effect, are treated surgically. However, recurrences are common (10 to 20%). Conservative management (medical) is used in patients who are asymptomatic or have minor symptoms. However, therapeutic failures, requiring surgical treatment, are common. The pathophysiology of CSH involves inflammation, angiogenesis, and clotting dysfunction. Self-perpetuation and rebleeding is thought to be caused by neo-membranes from the inflammatory remodeling of the dura-mater mainly fed by the distal branches of the middle meningeal artery (MMA). There are 13 ongoing registered RCTs in CSH, with the most common covering application of steroids, surgical techniques and tranexamic acid. Further to this, there are trials running on other pharmacological agents, and peri-operative management. Some industrial or academic trials are or will enroll in France in the next year in France. But to our best knowledge, none of these trials will the eventual benefits of the MMA embolization in both cases of medical and\u002For surgical management, and none will focus on the use of cyanoacrylates (CYA) for this purpose.\n\nPreliminary case series and nonrandomized retrospective studies have suggested that MMA embolization alone or as adjuvant therapy to surgery can decrease recurrences.\n\nThe investigators hypothesize that in both conditions of conservative or surgical managements, endovascular embolization of patients with CSH significantly reduces the risk of recurrence of CSH. The investigators choose the CYA as liquid embolic agent because of the pain and cost of the use of Ethylen Vinyl alcohol copolymer (EVOH) agents and its simplicity to be used.",[298],"Chronic Subdural Hematoma",[300,301,302,303],"Cyanoacrylate","Embolization","Middle meningeal artery","Recurrence of chronic subdural hematoma",{"date":84,"type":34},{"date":306,"type":34},"2023-03-28",{"date":308,"type":20},"2028-09-28",{"name":40,"class":41},11,{"id":312,"slug":4,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":318,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":330},"100437643","NCT04978948","Study of STIM1 Membrane Expression","Study of STIM1 Membrane Expression During Autoimmune Diseases","STIMEX","Inclusion Criteria:\n\n* Diagnosis of one of the autoimmune diseases\n\nExclusion Criteria:\n\n* Treatment with rituximab in the previous 12 months",{"count":319,"type":20},670,"The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM.\n\nThis would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.",[322],"Autoimmune Diseases",[150],{"date":84,"type":34},{"date":326,"type":34},"2021-05-11",{"date":328,"type":20},"2027-05",{"name":40,"class":41},4,{"id":332,"slug":4,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":51,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":90},"100423367","NCT04792931","Adult Autoimmune Myopathies (MAIA)","Adult Autoimmune Myopathies (MAIA): Clinical and Immunological Characterization, Constitution of a Patient Library","MAIA","Inclusion Criteria:\n\n* Clinical suspicion of Adult Inflammatory Myopathy\n* Social security affiliation\n\nExclusion Criteria:\n\n* Pregnant and lactating women\n* Patients unable to consent\n* Patients refusing to participate in the research.\n* Patients under legal protection",{"count":339,"type":20},60,[79],"This study corresponds to a monocentric prospective cohort of adult patients presenting a suspicion of idiopathic inflammatory myopathy. It will allows the constitution of an organized collection of longitudinal clinical data as well as collection of biological samples, including blood sample, urine, stool and muscle specimen.",[343],"Idiopathic Inflammatory Myopathies",{"date":61,"type":34},{"date":346,"type":34},"2022-05-20",{"date":348,"type":20},"2030-05-20",{"name":40,"class":41},{"id":351,"slug":4,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":274,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":51,"phases":359,"briefSummary":360,"conditions":361,"keywords":368,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":90},"100429254","NCT04869683","Biocollection in MyeloDysplastic Syndrome (P-MDS)","Biocollection in Patients With Myelodysplastic Syndrome (P-MDS)","P-MDS","Inclusion Criteria:\n\n* Major\n* patient with or suspected of myelodysplastic syndrome (WHO definition) at diagnosis and\u002For during follow-up, which is managed at the level of the Cancer-Hematology Institute of the Brest CHRU\n* Presence of biological material collected within the CRB\n* Patient's consent obtained\n\nExclusion Criteria :\n\n* Minor and pregnant woman\n* Lack of biological material collected within the CRB\n* Refusal to participate: lack of consent - Unable to consent\n* Patient under judicial protection: guardianship, curatorship ...",{"count":358,"type":20},150,[79],"Myelodysplastic syndromes (MDS) are chronic myeloid hemopathies characterized by ineffective hematopoiesis (with peripheral cytopenias) and which contrast with a marrow of normal richness. MDS is considered one of the four most common blood diseases. The incidence is estimated at 4,059 cases \u002F year in 2012 with an average age of 78 years in men and 81 years in women (INCA report, Cancers in France in 2015). The incidence increases with lengthening of the lifespan. The main risk of MDS is transformation to acute leukemia in 30 to 40% of cases. Treatment options depend on clinical, hematologic and chromosomal abnormalities. The prognosis is considered to be at low or high risk of developing acute leukemia. This distinction will therefore have an impact on the therapeutic solution (s). MDS exhibit clinical, morphological and genetic heterogeneity. It is therefore necessary to form subgroups of patients to better understand the physiopathogenesis of this pathology. The constitution of a biocollection will make it possible to search for clinical and biological prognostic markers in order to identify patients progressing to acute myeloid leukemia.",[362,363,364,365,366,367],"Myelodysplastic Syndromes","Myelodysplastic Anemia","Myelodysplastic Syndrome With Isolated Del(5Q)","Myelodysplastic Syndrome With Ring Sideroblasts","Acute Myeloid Leukemia With Multilineage Dysplasia","Chromosome Abnormality",[369,370,371,372],"MDS","5q deletion","ring sideroblasts","AML",{"date":61,"type":34},{"date":375,"type":34},"2022-10-19",{"date":377,"type":20},"2032-10-19",{"name":40,"class":41},{"id":380,"slug":4,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":16,"minAge":386,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":51,"phases":390,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":400},"100415109","NCT04685356","Effect of the IBAIP in Preterm Infants Neurodevelopment","Effect of the Infant Behavioral Assessment and Intervention Program (IBAIP) in Preterm Infants on Neurodevelopment at 2 Years Corrected Age","IBAIP","Inclusion Criteria :\n\n* Preterm infants born (including multiple pregnancies) at a gestational age between 25 weeks +0 days and 32 weeks + 6days.\n* Written informed consent of at least one of the parents \u002F legal guardian or 2 parents \u002F legal guardians depending on the family context\n* Normal neurological examination between 36 and 41 weeks of corrected age\n\nExclusion Criteria:\n\n* Intraventricular hemorrhage (III or IV), periventricular leukomalacia\n* Brain MRI abnormalities performed after 36 weeks of corrected age\n* Life-threatening pathology\n* Severe congenital abnomality\n* Severe maternal pathology (physical and \u002F or mental)\n* Parents whose native language is not French\n* Participation in another interventional study on the management of post-hospital neurodevelopment disorders","25 Weeks","32 Weeks",{"count":389,"type":20},240,[79],"Mortality in very preterm infants has decreased significantly over the past twenty years. However, neuromotor, behavioral and cognitive development disorders are more common in these children born before 33 weeks of gestation as compared to term born infants.\n\nThese neurodevelopmental disorders include difficulties with self-regulation, tone, posture or poor quality movements as well as inadequate responses to sensory simulation.\n\nPost-hospital discharge follow-up and interventionsof children born very preterm ares very heterogeneous in France. They are mainly carried out in a rehabilitation center, based on caregivers whereas IBAIP is carried out at home and family centered.\n\nEarly interventions during hospitalization or after discharge appear potentially of great interest in improving the neurodevelopemental outcome of the very preterm infants. Several early interventions have been developed and evaluated in other countries. These interventions are designed to be used early in life, mainly during the first 3 years of life, and are based on brain plasticity and intense synaptogenesis during this period of life.\n\nThe IBAIP (Infant Behavior Assessment and Intervention Program) was developed on the same theoretical foundations as the NIDCAP (Neonatal Individualized Development Care and Assessment Program). IBAIP consists of providing the child and his family with an intervention, at home, starting just before hospital discharge up to a 6 months corrected age. .The aim of IBAIP is to support developmental functions including infant's self-regulation and focus on improving the responsiveness of parents' infant interactions.",[393],"Premature Birth",{"date":84,"type":34},{"date":396,"type":34},"2022-11-08",{"date":398,"type":20},"2028-01-08",{"name":40,"class":41},9,{"id":402,"slug":4,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":16,"minAge":408,"maxAge":250,"enrollmentInfo":409,"targetDuration":4,"studyType":51,"phases":411,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":427},"100356009","NCT03915418","Validation of a Method of Screening for Sleep Disorders in Children With Cerebral Palsy, Using Connected Tools","Validation of a Simple Method of Screening for Sleep Disorders in Children With Cerebral Palsy, Using Connected Tools","SOUTIEN-PC","Inclusion Criteria:\n\n* Boy or girl between 6 and 15 years old\n* Confirmed diagnosis of cerebral palsy\n* GMFCS class\\> 3\n* Parents and child agreement\n\nExclusion Criteria:\n\n* Pharmacological treatment of sleep disorders\n* Diurnal and \u002F or nocturnal ventilatory support\n* Difficulty understanding and \u002F or participation\n* Subjects under 6 and over 15\n* Refusal to participate\n* Not affiliated with and not a beneficiary of a health insurance plan","6 Years",{"count":410,"type":20},140,[79],"Cerebral palsy (CP) is the most common cause of child disability. Nearly 40% of PC children suffer from sleep disorders, which are not routinely screened. The neuro-cognitive, physical and environmental morbidity of sleep disorders should require their diagnosis and management. Limited access to the reference exam (polysomnography or PSG) delays the diagnosis and only allows screening of these disorders for a limited number of PC children. The hypothesis of our study is that connected technologies could optimize screening for sleep disorders in PC children by selecting children requiring PSG exploration and specific management.",[414],"Sleep Disorders",[416,417,418,419,420],"Screening","sleep disorders","children","cerebral palsy","connected tools",{"date":61,"type":34},{"date":423,"type":34},"2021-01-12",{"date":425,"type":20},"2027-02",{"name":40,"class":41},6,{"id":429,"slug":4,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":274,"sex":434,"minAge":17,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":51,"phases":437,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":90},"100604969","NCT07156422","Pathophysiological Study of the Sensitive Scalp","SENSISCALP","Inclusion Criteria:\n\n* Adult women without dermatosis\n* Collection of free and informed consent\n* patient affiliated to a social security scheme\n\nFor the control group: Sensiscalp score = 0\u002F20 Sensitive scalp group: Sensiscalp score ≥ 3\u002F20 with pruritus sensation ≥ 2\u002F20\n\nExclusion Criteria:\n\n* Refusal to take part in the study\n* Dermatosis of the scalp (psoriasis, seborrhoeic dermatitis, etc.)\n* Pregnant and breast-feeding women\n* Women under legal protection (guardianship, curatorship)","FEMALE",{"count":436,"type":20},40,[79],"Sensitive skin is defined as a syndrome manifested by the occurrence of unpleasant sensations (tingling, burning, pain, pins and needles) in response to stimuli that should not normally cause them. These unpleasant sensations cannot be explained by lesions attributable to a specific skin disease. Sensitive skin can affect different parts of the body. The scalp is a site that is often affected, with specificity linked in particular to the presence of hair and different triggering factors (styling habits, wearing of head coverings, application of cosmetics to the scalp, etc.). Sensitive scalp affects around half the population, and can have an impact on the quality of life of sufferers, particularly those whose symptoms are very intense. Women are more likely than men to have a sensitive scalp, so in order to have a more homogenous study population, we chose to include 40 women. The pathophysiology of sensitive skin is imperfectly understood, and studies specific to the sensitive scalp are very rare. However, the pathophysiology of the sensitive scalp could be different because it is a hairy area, more innervated, and less exposed to environmental factors.",[440],"Sensitive Scalp",[442],"sensitive scalp","2026-06-19",{"date":130,"type":34},{"date":446,"type":34},"2026-01-28",{"date":448,"type":20},"2027-01",{"name":40,"class":41},{"id":451,"slug":4,"hasResults":11,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":51,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":310},"100590038","NCT06962215","The Impact of Paramedic Training in Simulation on the Experience of Patients Treated for Malignant Brain Tumors in Neurosurgery (IPSIMANON)","The Impact of Paramedic Training in Simulation on the Experience of Patients Treated for Malignant Brain Tumors in Neurosurgery","IPSIMANON","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Patient covered by a social security scheme\n* Patient signed informed consent form\n* Patient found to have a brain tumor (potentially malignant, primary or secondary if this is the mode of entry into the disease)\n* Hospitalization in the Neurosurgery Department at the time of tumor discovery, before the histological diagnosis is announced.\n\nExclusion Criteria:\n\n* Patients with a personal history of cancer\n* Patient without family AND unable to receive information",{"count":253,"type":20},[79],"The goal of this clinical trial is to demonstrate that simulation training for paramedical staff in neurosurgery departments, in announcing and accompanying patients with a brain tumor, improves patient satisfaction when a (potentially malignant) brain tumor is discovered, compared with usual care.\n\nThe main question it aims to answer is:\n\n\\- Are patients more satisfied (as measured by scores on the EORCT IN-PATSAT32 questionnaire) with their neurosurgical hospitalization following the discovery of a brain tumor in centers where paramedics have been trained by simulation?\n\nResearchers will compare the results of the EORTC IN-PATSAT32 questionnaire to determine whether paramedic training improves patient satisfaction between simulation-trained and untrained centers.\n\nParticipants will be asked to complete the EORT IN-PATSAT32 questionnaire at the end of their hospital stay.",[461],"Brain Tumor Adult",[463,464,465,466],"Brain tumor","Simulation Training","Paramedical","Neurosurgery",{"date":468,"type":34},"2026-06-23",{"date":470,"type":34},"2025-05-15",{"date":472,"type":20},"2027-10",{"name":40,"class":41},{"id":475,"slug":4,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":51,"phases":483,"briefSummary":486,"conditions":487,"keywords":489,"overallStatus":492,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":90},"100620465","NCT07357974","Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET\u002FCT in Patients With PAH","Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET\u002FCT in Patients With PAH: a Pilot Study","SOFAPI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum PVR of ≥ 4 Wood units and pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of WHO PAH Group 1 in any of the following subtypes:\n\n  * Idiopathic PAH\n  * Heritable PAH\n  * Drug\u002Ftoxine-induced PAH\n  * PAH associated with connective tissue disease\n  * PAH associated with simple, congenital systemic-to- pulmonary shunts at least 1year following repair\n* Patients under bi or tri-background-therapy\n* Symptomatic PAH classified WHO FC II or III\n* Patients will be started on Sotatercept\n* Ability to adhere to study visit schedule and understand and comply with all the protocol requirement.\n* Ability to understand and provide written informed consent\n\nExclusion Criteria:\n\n* Diagnosis of PH WHO Groups 2, 3, 4, or 5\n* Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis associated PAH, pulmonary veno occlusive disease and pulmonary capillary hemangiomatosis.\n* Hemoglobin at screening above gender-specific ULN, per local laboratory test\n* Pregnant or breastfeeding women\n* Any of the following clinical laboratory values at the Screening visit:\n\n  * eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 (as defined by MDRD equation)\n  * Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels \\> 3 × ULN\n  * Platelet count \\\u003C 50,000\u002Fmm3 (\\\u003C 50.0 × 109\u002FL)\n* Known allergic reaction to sotatercept (ACE-011), its excipients, or luspatercept",{"count":482,"type":20},15,[484,485],"PHASE1","PHASE2","Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterized by structural changes in the pulmonary arteries, leading to increased pulmonary vascular resistance and elevated pulmonary arterial pressure and, if untreated, right heart failure. Diagnosis requires a comprehensive evaluation, including right heart catheterization performed in specialized centers.\n\nDespite advances in the understanding and management of the disease, PAH remains a severe condition. Current approved therapies primarily target three key pathways involved in endothelial dysfunction: the endothelin, nitric oxide, and prostacyclin pathways. Pulmonary arterial remodeling is characterized by alterations in endothelial cells, smooth muscle cells, and fibroblasts, with fibroblast activation and macrophage involvement contributing to disease progression.\n\nTwo positron emission tomography\u002Fcomputed tomography (PET\u002FCT) imaging approaches are currently under investigation in PAH. \\[⁶⁸Ga\\]Ga-FAPI PET\u002FCT targets activated fibroblasts and enables noninvasive assessment of fibroblast activity and tissue remodeling. \\[⁶⁸Ga\\]Ga-MAA lung perfusion PET\u002FCT is an emerging imaging technique that provides higher spatial resolution and sensitivity than conventional lung perfusion imaging and allows evaluation of regional pulmonary perfusion.\n\nSotatercept is a novel fusion protein that modulates signaling within the transforming growth factor-beta (TGF-β) superfamily by binding select ligands involved in vascular remodeling. Its mechanism of action is distinct from that of currently approved PAH therapies. Sotatercept has been evaluated in clinical development programs, including the PULSAR and STELLAR studies. Reported adverse events include epistaxis, dizziness, increased hemoglobin levels, and changes in blood pressure.\n\nThis study is designed with the following objectives:\n\nPrimary objective: To assess pulmonary vascular remodeling in patients with PAH using \\[⁶⁸Ga\\]Ga-FAPI PET\u002FCT imaging.\n\nSecondary objectives: To evaluate \\[⁶⁸Ga\\]Ga-FAPI uptake and regional lung perfusion using \\[⁶⁸Ga\\]Ga-MAA lung perfusion PET\u002FCT imaging at predefined study time points.",[488],"Pulmonary Arterial Hypertension (PAH)",[490,491],"[68Ga]Ga-FAPI PET\u002FCT (FAPI)","[68Ga]Ga-MAA lung perfusion PET\u002FCT","NOT_YET_RECRUITING","2026-06-15",{"date":495,"type":34},"2026-06-16",{"date":497,"type":20},"2026-07-15",{"date":499,"type":20},"2028-01-01",{"name":40,"class":41},{"id":502,"slug":4,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":274,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":90},"100614495","NCT07280338","Emotional Intelligence and Chronic Orofacial Pain","IEDOF","Inclusion Criteria:\n\nFor all subjects:\n\nMajor subject\n\n* Non-opposition obtained\n* For subjects in the TMD group:\n\nDiagnosis of temporomandibular dysfunction -No other diagnosis of chronic pain\n\nFor subjects in the control group:\n\n-No diagnosis of chronic pain\n\nNon inclusion Criteria:\n\n* Subject not understanding French\n* Subject under legal protection (guardianship or curatorship)\n* Refusal to participate",{"count":508,"type":20},88,"Chronic pain, lasting more than three months, is a widespread health issue that negatively impacts daily life, leading to significant emotional distress and functional impairment. Emotional intelligence, defined as the ability to recognize and manage one's own emotions as well as those of others, has been linked to better communication skills and reduced stress, which is a well-known risk factor for chronic pain. Studies have highlighted a correlation between emotional intelligence and certain chronic pain conditions, such as fibromyalgia and migraines. However, no research has yet explored its role in painful temporomandibular disorders (TMD). Given the strong involvement of psychosocial factors in TMD etiology, a better understanding of these elements could improve pain management and pave the way for preventive interventions.",[511],"Chronic Pain",[513],"Emotional intelligence",{"date":495,"type":34},{"date":516,"type":34},"2026-02-09",{"date":518,"type":20},"2027-02-09",{"name":40,"class":41},{"id":521,"slug":4,"hasResults":11,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":51,"phases":528,"briefSummary":529,"conditions":530,"keywords":531,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":42},"100550031","NCT06441773","Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated With Immunotherapy and Chemotherapy in the Maintenance Phase","REHABIM","Inclusion Criteria:\n\n* Histologically proven stage IV non-small cell lung cancer patient\n* First-line treatment with chemotherapy combined with immunotherapy in the maintenance phase\n* Adenocarcinoma patient: maintenance with Alimta combined with pembrolizumab\n* Squamous cell carcinoma patient: maintenance with pembrolizumab alone\n* Age of at least 18 years\n* Performance status of 0 or 1\n* Estimated life expectancy \\> 12 weeks\n* No contraindications to respiratory rehabilitation\n* Adequate organ function, demonstrated by laboratory results within the last 3 weeks, allowing maintenance treatment:\n* Normal liver function: bilirubin \\\u003C 1.5 x ULN, ALT and AST \\\u003C 2.5 x ULN or \\\u003C 5 x ULN in the case of liver metastases.\n* Renal function (creatinine clearance calculation of at least \\> 45 mL\u002Fmin).\n* Hematological function: absolute neutrophil count \\> 1.5 x 10\\^9\u002FL and\u002For platelets \\> 100 x 10\\^9\u002FL, hemoglobin \\> 8 g\u002FdL.\n* Informed consent to participate in the study must be signed\n* Patient must be affiliated with or beneficiary of social security\n\nExclusion Criteria:\n\n* Small cell lung cancer, mesothelioma, neuroendocrine lung cancer\n* Patients with orthopedic disorders preventing respiratory rehabilitation that, in the investigator's opinion, could interfere with respiratory rehabilitation\n* Unresolved toxicity from previous treatment of grade \\> 1 (except alopecia) that, in the investigator's opinion, could interfere with respiratory rehabilitation\n* Symptomatic brain metastases (corticosteroid treatment is allowed if the doses administered are stable for at least one month before inclusion)\n* Bone metastases preventing respiratory rehabilitation\n* Contraindication to respiratory rehabilitation\n* Uncontrolled infection\n* Pregnancy and breastfeeding\n* Surgery within two months prior to inclusion that could interfere with respiratory rehabilitation\n* Persons under legal protection (guardianship or curatorship) or deprived of liberty",{"count":527,"type":20},96,[79],"Lung cancer is highly prevalent, with approximately 46,363 new cases in 2018, accounting for 20.6% of cancer deaths in France. At diagnosis, 70% of patients have advanced or metastatic cancer, treatable only by palliative care. Respiratory rehabilitation aims to reduce symptoms, enhance performance, increase autonomy, and improve patients\\' quality of life. While effective for COPD patients and other conditions causing dyspnea, its benefits in advanced, non-operable lung cancer are less studied. Some studies have shown the feasibility and safety of respiratory rehabilitation, but few have compared its impact on non-operable lung cancer patients or assessed its effect on quality of life. The main objective of the proposed study is to evaluate the impact of a respiratory rehabilitation program on the quality of life of patients with non-small cell lung cancer (NSCLC) undergoing maintenance chemotherapy and immunotherapy, compared to a control group receiving standard care.",[194],[532],"Respiratory rehabilitation",{"date":534,"type":34},"2026-06-17",{"date":536,"type":34},"2025-11-21",{"date":538,"type":20},"2028-11-21",{"name":40,"class":41},{"id":541,"slug":4,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":51,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":552,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":90},"100537257","NCT06275477","68Gallium-FAPI46 PET\u002FCT Imaging in Chronic Inflammatory and Fibrotic Diseases","PARADISE","Inclusion Criteria:\n\n* Patient aged 18 or over.\n* Affected by one of the pathologies concerned by the study (see Table 4)\n* Satisfying the consensus classification criteria for the pathology (Table 3).\n* Satisfying the corresponding clinical situation (Table 3).\n* Negative urine pregnancy test for women of childbearing age.\n* Affiliated with or benefiting from social security.\n* Informed consent (personally dated and) signed by the participant or any representatives (impartial witness\u002Ftrusted person).\n\nExclusion Criteria:\n\n* Patients unable to consent.\n* Incapacitated adults.\n* Pregnant or breastfeeding women.\n* Patients refusing to participate in research.\n* Known active cancer.\n* Women of childbearing potential unwilling to use appropriate contraception (definitions given in Annex 1).",{"count":547,"type":20},390,[79],"This single-center pilot study is designed to explore the preliminary utility of the \\[68Ga\\] Ga-FAPI imaging agent in positron emission tomography (PET) combined with computed tomography (CT) for a range of chronic inflammatory and fibrosing diseases. The study focuses on the potential of \\[68Ga\\] Ga-FAPI, a novel radiotracer targeting Fibroblast Activation Protein (FAP), to improve diagnostic accuracy in various medical conditions. Thirteen distinct clinical situations have been selected for this investigation, including rheumatoid arthritis, liver fibrosis, and systemic lupus, among others. This approach aims to ascertain the value of further clinical development in each area and refine the use of this imaging modality in routine care for both initial evaluation and ongoing monitoring of these diseases.",[551],"Inflammatory Disease",{"date":495,"type":34},{"date":554,"type":34},"2025-03-13",{"date":556,"type":20},"2028-10-05",{"name":40,"class":41},{"id":559,"slug":4,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":564,"targetDuration":4,"studyType":51,"phases":566,"briefSummary":567,"conditions":568,"keywords":571,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":90},"100447225","NCT05103670","Ventilation\u002FPerfusion PET\u002FCT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism","EOLE","Inclusion Criteria:\n\n* Patient included in the RAMBO study, whose inclusion criteria are: Age ≥ 18 years; Patient treated with at least 3 months and up to 8 months of anticoagulation for an acute symptomatic PE diagnosed according the ESC and ACCP guidelines; Patients who have a PembQol score ≥ 10% and whose total scores for the subgroups Q1 (dyspnea) and Q4 (impact of daily life) are ≥ 10%.\n* Patients planned to be randomized\n* Abnormal conventional V\u002FQ scan at V1\n* Give consent to participate to the EOLE study\n\nExclusion Criteria:\n\n* Non inclusion criteria of the RAMBO trial:\n* Previsible inability to perform the effort test and\u002For PR\n* Presence of CTEPH according to international guidelines\n* Patients treated for acute PE with anticoagulants for more than 8 months\n* Active cancer or in remission for less than two years\n* Dyspnea post - COVID due to parenchymal injuries\n* Post-COVID hyperventilation syndrome without pulmonary vascular perfusion sequelae\n* Physical or psychological inability to undertake PR\n* Isolated or more distal segmental PE\n* Neuro-muscular disease with PR contraindication.\n* Cardiac insufficiency (unstable coronary artery disease)\n* Severe respiratory failure (long-term oxygen therapy, pulmonary hypertension)\n* Chronic dyspnea MMRC ≥ 2 before PE\n* Cardiac or respiratory rehabilitation in the previous year\n* Indication to urgent PR within 6 months at the time of inclusion\n* Life expectancy of less than 12 months\n* Inability to give consent\n* Patient under guardianship or curatorship\n* Patient deprived of liberty by an administrative or judicial decision\n* Patient has not social security affiliation or who don't beneficiary of such social security\n\nAfter initial PR work up, patients with following criteria cannot be included:\n\n* Incapacity to perform the effort test\n* Effort test stopped because of hemodynamic intolerance\n* Cardiac failure discovered after PR work up",{"count":565,"type":20},32,[79],"In patients with pulmonary embolism (PE), after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases.\n\nThe \"RAMBO\" trial is a French academic, multicenter, randomized (1:1 ratio), parallel arm, controlled, that aimed to assess the efficacy of pulmonary rehabilitation (PR) on the quality of life in patients with an acute symptomatic PE treated with anticoagulant therapy during at least 3 months and who present an impairment of quality of life and\u002For persistent dyspnea despite anticoagulant therapy.\n\nVentilation\u002FPerfusion (V\u002FQ) PET\u002FCT is a novel imaging modality for the assessment of regional lung function. The same carrier molecules as conventional V\u002FQ imaging are used, but they are labeled with 68Gallium, a ß+ isotope, instead of 99mTc, allowing acquisition of images with PET technology.\n\nThe EOLE study is an ancillary pilot study of the RAMBO trial, in which patients will benefit, in addition to the extensive work up scheduled as per study protocol, from a V\u002FQ PET\u002FCT scan before and after PR. The aim of the study is to assess the impact of PR on regional lung function with lung V\u002FQ PET\u002FCT imaging.",[569,570],"Pulmonary Embolism","Dyspnea",[572,573,574],"Ventilation\u002Fperfusion PET\u002FCT","Galligas","68Ga-MAA",{"date":495,"type":34},{"date":577,"type":34},"2023-06-22",{"date":579,"type":20},"2026-12-22",{"name":40,"class":41},""]